Abeille Pharmaceuticals, Inc. Appoints Scientific Advisory Committee

PRINCETON, N.J., Nov. 14 /PRNewswire/ -- Abeille Pharmaceuticals, Inc., a product development company focusing on the development and commercialization of novel dosage forms and unique, proprietary combinations of existing drugs, today announced the appointment of its new nine member Scientific Advisory Committee (SAC).

"The Scientific Advisory Committee held its first meeting last month. We are totally committed to having an active SAC. The SAC will play an important role in assisting Abeille to refine its clinical and regulatory strategy for its pipeline products, as well as being a valuable resource for identifying products for the future," said Dr. Kalpana Patel, VP Strategic Planning and Alliance Management, and Chairman of the SAC.

"Abeille is very pleased to have such renowned scientists and clinicians on our advisory committee. Their knowledge of the pharmaceutical industry and their diverse, yet complimentary, areas of expertise will constitute a vital resource for us," stated Suresh Borsadia, President and CEO of Abeille Pharmaceuticals. "I look forward to the Committee's continuing contribution to Abeille's current products and their assistance as we continue to advance, and expand, our product pipeline."

The members of the SAC are: John G. Babish, Ph.D. Chairperson of BIOnexus, Cornell University's technology transfer company, Senior Vice President of Ashni Naturaceuticals, Inc. Douglas Flanagan, Ph.D. Professor of Pharmaceutics at the University of Iowa and Director of Pharmaceutical Services, an FDA approved outsourcing facility at the University of Iowa that provides development and GMP manufacturing services. Om P. Ganda, M.D. Associate Clinical Professor of Medicine at Harvard Medical School and Director of the Lipid Clinic at the Joslin Diabetes Center in Boston, Massachusetts. Mario A. Gonzalez, Ph.D. President of P'Kinetics International, a biopharmaceutics and pharmacokinetics research company; Adjunct Professor, University of Florida's College of Pharmacy, Gainesville, Florida. Richard J. Gralla, M.D. President of the NY Lung Cancer Alliance, New York, NY. Past-President of the Multinational Association of Supportive Care in Cancer. David A.H. Lee, M.D., Ph.D. Executive Vice President of Research and Development and Chief Science Officer at Endo Pharmaceuticals, Inc. Formerly, Vice President of Research and Development of CoCensys, Inc., and Solvay Pharmaceuticals. Rajendra Patel, M.D. Practicing Cardiologist with the Gardenstate Cardiology Associates and a Staff Cardiologist at Our Lady of Lourdes Hospital, the Virtua Health System and the Kennedy Health System. Robert Pollock, M.S., RPh. Senior Vice President of Lachman Consultant Services, Inc. Formerly, Acting Deputy Director of the Office of Generic Drugs, CDER, FDA, Rockville, MD. Sander J. Robins, M.D. Professor of Medicine at Boston University School of Medicine, Boston, MA; Laboratory Director of the Framingham Heart Study; Associate Editor of the Journal of Lipid Research. A more detailed biography for each SAC member may be found on our website. About Abeille Pharmaceuticals

Abeille Pharmaceuticals, Inc. is a privately-held pharmaceutical company based in Princeton, New Jersey. The Company is focused on the formulation of products by applying advanced delivery technologies to existing drugs. These advanced delivery technologies include oral controlled release and transdermal delivery systems. The new products may benefit patients by requiring a lower dose of medicine, reduced side effects and easier administration of medication, thereby encouraging a patient to use the medication as prescribed. Abeille is dedicated to the development and commercialization of products that address unmet medical needs and improve the quality of life for patients. The Company's initial focus will be on drugs used to treat oncology related discomforts, diabetes and metabolic disorders, and CNS disease conditions.

For more information, visit our website www.abeillepharma.com

Abeille Pharmaceuticals, Inc.

CONTACT: Suresh Borsadia, President and CEO of Abeille Pharmaceuticals,Inc., +1-609-951-2204, or fax, +1-609-951-2223, orsborsadia@abeillepharma.com